Previous Year Event Recaps

2024 Agenda

7:15 am	Sign-In, Continental Breakfast, Poster Set-Up
8:00 am	Welcome/Purpose of Symposium Susan F. Smith Center Leaders
8:10 am	J. Dirk Iglehart, M.D., Visiting Scholar Lecture *Harnessing omics and AI for precision breast oncology* Christina Curtis, PhD, MSc RZ Cao Professor of Medicine, Genetics & Biomedical Data Science Director AI and Cancer Genomics Director, Breast Cancer Translational Research Investigator, Chan Zuckerberg Biohub Stanford University (35-40 min talk, 10 mins questions)
9:00 am	SESSION I:Genomics Chair: Gerburg Wulf
9:00 – 9:45 am	3 oral presentations (10 mins each; 5 mins questions) Abstract #1 Okoh Frimpong: Chemoproteomic Evaluation of PROTACs Targeting Estrogen Receptor Alpha in ER+ Breast Cancer Abstract #4 Zheqi Li: KDM4C histone demethylase prevents histone cleavage in breast cancer Abstract #9 Jessica St. Laurent: Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in endometrioid carcinomas
9:45 am	POSTER SESSION 9:45 am – 10:30 am – Open Posters
10:30 am	SESSION II: Risk, Prevention & Disparities/Clinical Chair: Sara Tolaney
10:30 – 11:15 am	3 oral presentations (10 mins each; 5 mins questions) Abstract #12 Haohui Duan: BRCA2 haploinsufficiency induces P53 degradation in primary mammary epithelial cells – a crucial early event in breast tumor promotion Abstract #18 Jennifer Mongiovi: Associations between intrauterine device use and ovarian cancer risk among 11 population-based case-control studies Abstract #21 Xingping Qin: Safely targeting endogenous and therapy-enhanced BCL-XL dependence in ovarian cancer using the PROTAC DT2216
11:15 am	M. Patricia Cronin Memorial Lecture *Why listening to women matters in ovarian cancer research* Sarah M. Temkin, M.D. Associate Director for Clinical Research Office of Research on Women’s Health Office of the Director, NIH (35-40 min talk, 10 mins questions)
12:05 pm	Lunch and Open Posters 12:05 – 1:15pm
1:15 pm	SESSION III: Drug Resistance/Animal Models Chair: Patricia Donahoe
1:15 – 2:15 pm	4 oral presentations (10 mins each; 5 mins questions) Abstract #30 Carman Li: Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer Abstract #32 Yusuke Matoba: Targeting Bcl-XL is a potential novel therapy for uterine serous cancer Abstract #35 Ramya Ravindranathan: PARG inhibitor sensitivity is correlated with accumulation of single strand DNA gaps in preclinical models of ovarian cancer Abstract #40 Ting Liu: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBC.
2:15 pm	SESSION IV: Tumor Microenvironment/Immunology Chair: Jean Zhao
2:15 – 3:00 pm	3 oral presentations (10 mins each; 5 mins questions) Abstract #41 Sara Busatto: Breast cancer-derived extracellular vesicles modulate the endocytic metabolism and morphodynamics of the endothelial cells of the blood-brain barrier Abstract #43 Maeva Chauvin: Targeting Follistatin-like 3 to reverse immunotherapy resistance in ovarian cancer Abstract #46 Adam Nelson: Immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC)
3:00 pm	Announcement of Awards and Adjourn

Hide

2023 Agenda

7:15 am	Sign-In, Continental Breakfast, Poster Set-Up
8:00 am	Welcome/Purpose of Symposium Susan F. Smith Center Leaders
8:10 am	M. PATRICIA CRONIN MEMORIAL LECTURE “STICs make tumors nervous” Ronny Drapkin, M.D., Ph.D. Franklin Payne Chair in Gynecologic Oncology Director, Penn Ovarian Cancer Research Center Director, Gynecologic Cancer Research, Basser Center for BRCA Assistant Dean, Department of Defense Ovarian Cancer Academy (35-40 min talk, 10 mins questions)
9:00 am	SESSION I: Genomics Chair: Gerburg Wulf
9:00 – 9:45 am	3 oral presentations (12 mins each); 3 mins questions
Abstract #25	Dominik Glodzik: Timing onset of homologous recombination deficiency before cancer diagnosis in BRCA1/2 mutation carriers
Abstract #26	Po-Han Lin: Genomics and transcriptomics landscape of early pathogenesis of the BRCA1/2-associated breast cancer
Abstract #27	Stefania Morganti: Clonal hematopoiesis of indeterminate potential (CHIP) after (neo)adjuvant chemotherapy (CT) versus endocrine therapy (ET) for early breast cancer (eBC): the CIRCE-eBC prospective cohort study
9:45 am	POSTER SESSION 9:45 am – 10:30 am – Open Posters
10:30 am	SESSION II: Risk, Prevention & Disparities/Clinical Chair: Sara Tolaney
10:30 – 11:30 am	4 oral presentations (12 mins each); 3 mins questions
Abstract #5	Cheng Peng: Regular Aspirin Use and Long-term Breast Cancer Survival
Abstract #19	Joseph Dottino: Who is first in line? Trends in use of poly-ADP ribose polymerase inhibitors (PARPi) among commercially insured women with ovarian cancer
Abstract #22	Filipa Lynce: A phase Ib study of sapacitabine (sapa) and olaparib (ola) in patients (pts) with BRCA1/2-mutated (BRCA1/2m) metastatic breast cancer (MBC)
Abstract #31	MacLean Sellars: Personalized targeted circulating tumor DNA (ctDNA) to monitor response to combined neoantigen vaccine and immune checkpoint blockade in ovarian cancer
11:30 am	J. DIRK IGLEHART, M.D., VISITING SCHOLAR LECTURE “Regulatory Strategies to Address Unmet Need in Breast Cancer” Tatiana M. Prowell, M.D. Breast Cancer Scientific Liaison, U.S. Food and Drug Administration Associate Professor of Oncology, Breast Cancer Program, Johns Hopkins University School of Medicine (35-40 min talk, 10 mins questions)
12:15 pm	Lunch and Open Posters 12:15 – 1:15pm
1:15 pm	SESSION III: Drug Resistance/Animal Models Chair: Patricia Donahoe
1:15 – 2:15 pm	4 oral presentations (12 mins each); 3 mins questions
Abstract #43	Joshua Rivera: Single Cell Transcriptomics Reveals Putative Tumor Promoting Subpopulation in Brca1 Mutant Breast Cancer Mouse Model
Abstract #45	Alexandre da Costa: The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance
Abstract #57	Bogang Wu: Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer
Abstract #59	Oladapo Yeku: Antibody Drug Conjugates against MUC16 for Ovarian Cancer
2:15-2:30	15-Minute Break
2:30 pm	SESSION IV: Tumor Microenvironment/Immunology Chair: Jean Zhao
2:30 – 3:30 pm	4 oral presentations (12 mins each); 3 mins questions
Abstract #32	Triet Bui: The Single-Cell Trajectory of Immune Escape During DCIS-IDC Progression
Abstract #34	Maeva Chauvin: The role of cancer-associated mesothelial cells in the ovarian tumor microenvironment
Abstract #35	Jenny Hogstrom: Modeling drug resistance in ER+ breast cancer using patient-derived organoid cultures and cancer-associated fibroblasts
Abstract #62	Jeffrey Patterson-Fortin: Polymerase θ inhibition activates the cGAS-STING pathway in BRCA1-deficient breast cancer
3:30 pm	Announcement of Awards and Adjourn

Hide

2020 Agenda

Please note: This event was canceled in 2020 due to Covid

7:15 am	Sign-In, Continental Breakfast, Poster Set-Up
8:00 am	Welcome/Purpose of Symposium Susan F. Smith Center Leaders
8:10 am	M. Patricia Cronin Memorial Lecture “Nervous Tumors: Cancer-derived vesicles promote nerve recruitment and treatment resistance in ovarian cancer” Ronny Drapkin, MD, PhD The Franklin Payne Associate Professor of Pathology Director, Penn Ovarian Cancer Research Center; Director, Gynecologic Cancer Research, Basser Center for BRCA; Director, Abramson Translation Center of Excellence in Ovarian Cancer, University of Pennsylvania
9:00 am	SESSION I: Genomics Chair: Gerburg Wulf Arthur Lambert:p63/p73 are transcriptional drivers of cancer stem cells residing in an intermediate EMT state Rebecca Porter:Repeatome profiling identifies novel molecular biomarkers and therapeutic targets in epithelial ovarian cancer Nobuhiro Takahashi:A Personalized Approach to Identify and Target Ovarian Cancer Liabilities
9:45 am	Poster Session
10:30 am	SESSION II: Risk/Prevention/Clinical Chair: Sara Tolaney Tengteng Wang:Post-diagnosis diabetes risk reduction diet and survival following breast cancer Tanya Keenan:A phase II study of cisplatin and the Wee1 inhibitor adavosertib in metastatic triple-negative breast cancer (mTNBC) Jan Heng:Tobacco use, alcohol consumption, and breast cancer somatic genomic alterations
11:15 am	J. Dirk Iglehart, MD Visiting Scholar Lecture “Regulatory Strategies to Address Unmet Need in Breast Cancer” Tatiana M. Prowell, MD Breast Cancer Scientific Liaison, U.S. Food and Drug Administration Associate Professor of Oncology, Breast Cancer Program, Johns Hopkins University School of Medicine
12:00 pm	Lunch and Open Posters
1:00 pm	SESSION III: Drug Resistance/Animal Models Chair: Patricia Donahoe Masa Aleckovic:Mammary tumor prevention by inhibition of TGF-beta signaling Akshaya Chandrasekaran:PAX8-directed nanotherapeutics for high-grade serous ovarian cancer Jia Zhou:Polymerase Theta Inhibition Overcomes PARP Inhibitor Resistance
1:45 pm	SESSION IV: Tumor Biology/Immunology Chair: Jean Zhao Johann Bergholz:Potentiating immunotherapy in PTEN-deficient triple-negative breast cancer by isoform-specific PI3Kβ inhibition Yihao Li:Enhancer activation mediates resistance to FGFR inhibitors in triple-negative breast cancer Francisco Hermida-Prado:Role of the estrogen receptor axis in the modulation of the immune response in ER+ Breast Cancers
2:30 pm	Announcements of Awards and Adjourn

Hide

2019 Agenda

7:15 am	Sign-In, Continental Breakfast, Poster Set-Up
8:00 am	Welcome/Purpose of Symposium Susan F. Smith Center Leaders
8:10 am	M. Patricia Cronin Memorial Lecture “Loss of Base Excision Repair Drives Drug Resistance in BRCA2 Mutant Ovarian Cancer" Shailja Pathania, Ph.D. Assistant Professor, Center for Personalized Cancer Therapy University of Massachusetts Boston
9:00 am	SESSION I: Genomics Chair: Gerburg Wulf Rajula Elango: Coordination of stalled replication fork repair by Fanconi anemia gene product Slx4 Doga Gulhan: Detecting the mutational signature of homologous recombination deficiency in clinical samples Mihriban Karaayvaz: Aneuploidy and suppressed DNA damage response define haploinsufficiency in breast tissues of BRCA2 mutation carriers
9:45 am	Poster Session
10:30 am	SESSION II: Risk/Prevention/Clinical Chair: Rulla Tamimi Emma McGee: Plasma osteoprotegerin and breast cancer risk: A nested case-control study within the Nurses’ Health Study II Oana Zeleznik: Mammogram-derived texture features and risk of breast cancer Hanneke Poort: Predictors and Trajectories of Fatigue in Ovarian and Uterine Cancer
11:15 am	J. Dirk Iglehart, MD Visiting Scholar Lecture “Unraveling the drivers of breast cancer: phenotypic plasticity meets mutations in long-tail genes” Charlotte Kuperwasser, PhD Director, Raymond and Beverly Sackler Convergence Laboratory (RBSCL) Professor Developmental, Molecular & Chemical Biology Tufts University School of Medicine (35-40 min talk, 10 mins questions)
12:00 pm	Lunch and Open Posters
1:00 pm	SESSION III: Drug Resistance/Animal Models Chair: Patricia Donahoe Carlos Gil del Alcazar: Immune related strategies for prevention of breast tumor initiation and progression Akshaya Chandrasekaran: PAX8-directed nanotherapeutics for high grade serous ovarian cancer Prabha Sarangi: The TRIP13 ATPase mediates PARP inhibitor resistance by promoting homologous recombination
1:45 pm	SESSION IV: Tumor Biology/Immunology Chair: Jean Zhao Kirsten Kubler: Tamoxifen-associated uterine corpus cancer is characterized by the lack of mutational activation in the PI3K-AKT-mTOR pathway Sonia Iyer: Novel Syngeneic Mouse Models of High-Grade Serous Ovarian Carcinoma reveal distinct tumor microenvironments for Homologous Recombination -Deficient and -Proficient tumors Jennifer Guerriero: Harnessing Macrophages in Triple Negative Breast Cancer (TNBC) to Overcome PARP Inhibitor Resistance
2:30 pm	Announcements of Awards and Adjourn

Hide

2018 Agenda

7:15 am	Sign-In, Continental Breakfast, Poster Set-Up
8:00 am	Welcome/Purpose of Symposium Alan D’Andrea, M.D. - Ursula Matulonis, M.D. - Eric Winer, M.D.
8:10 am	KATHRYN FOX SAMWAY MEMORIAL LECTURE: “Mechanisms that maintain genome stability” Andre Nussenzweig, Ph.D. NIH Distinguished Investigator, Laboratory of Genome Integrity National Cancer Institute, Center for Cancer Research
9:00 am	SESSION I: Genomics Chair: Gerburg Wulf Hui Liu: Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer Johnathan R. Whetstine: Balancing Lysine Methylation Impacts Site-Specific DNA Copy Gains Associated with Aggressive Disease Nicholas A. Willis: BRCA1 suppresses genomic instability specific to defects in stalled fork repair in mammalian cells
9:45 am	Poster Session
10:30 am	SESSION II: Clinical/Translational Chair: Patricia Donahoe Adrienne G. Waks: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab Anniina Färkkilä: DNA damage- and immune profiling with highly multiplexed tissue immunofluorescence (t-CycIF) in high-grade serous ovarian cancer Golnaz Morad: Using proteomics profiling to elucidate the interactions of breast cancer-derived exosomes with the blood brain barrier
11:15 am	M. PATRICIA CRONIN MEMORIAL LECTURE: “Reprogramming the tumor microenvironment and T cells for ovarian cancer immunotherapy” Kunle Odunsi, M.D., Ph.D. Cancer Center Deputy Director, The M. Steven Piver Professor and Chair, Department of Gynecologic Oncology, Executive Director, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center
12:00 pm	Lunch and Open Posters
12:45 pm	SESSION III: Risk/Prevention Chair: Rulla Tamimi Cheng Peng: Transcriptomic network analysis reveals molecular mechanisms linking radon exposure to breast cancer etiology in breast tumor and tumor-adjacent tissues Claire H. Kim: Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression in the Nurses’ Health Study II Motohiro Kano: Concurrent MIS/AMH treatment during chemotherapy preserves the ovarian reserve and fertility
1:30 pm	SESSION IV: Tumor Biology Chair: Jean Zhao Johann Bergholz: PI3Kβ mediates immune evasion in PTEN-deficient triple-negative breast cancer Constantia Pantelidou: The covalent CDK12 Inhibitor MFH290 has monotherapy activity in homologous recombination repair-deficient breast and ovarian cancer models and reverses PARP inhibitor resistance Sarah J. Hill: Rapid assessment of DNA repair inhibitors and checkpoint blockade efficacy in short term patient-derived ovarian cancer organoids
2:15 pm	Special Seminar: “Targeting Galectin 3 Action for Tumor Growth Suppression and Metastasis” David Spriggs, M.D.
2:30 pm	Annoucements of Awards and Adjourn

Hide